Zoetis Inc. $ZTS Shares Purchased by Spinnaker Trust

Spinnaker Trust raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 37.1% during the second quarter, Holdings Channel.com reports. The institutional investor owned 1,823 shares of the company’s stock after buying an additional 493 shares during the period. Spinnaker Trust’s holdings in Zoetis were worth $284,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Nova Wealth Management Inc. acquired a new stake in Zoetis during the 1st quarter valued at $25,000. 1248 Management LLC acquired a new stake in Zoetis during the 1st quarter valued at $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis during the first quarter worth $29,000. Cornerstone Planning Group LLC boosted its holdings in shares of Zoetis by 79.3% during the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock worth $30,000 after purchasing an additional 88 shares during the last quarter. Finally, REAP Financial Group LLC boosted its holdings in shares of Zoetis by 201.5% during the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of Zoetis stock opened at $143.77 on Friday. Zoetis Inc. has a twelve month low of $139.34 and a twelve month high of $183.11. The stock has a market capitalization of $63.72 billion, a P/E ratio of 24.75, a PEG ratio of 2.31 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The business’s fifty day moving average price is $147.40 and its 200 day moving average price is $153.41.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The firm had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The firm’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st will be given a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 annualized dividend and a yield of 1.4%. Zoetis’s dividend payout ratio (DPR) is 34.42%.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on ZTS shares. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Piper Sandler raised their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. UBS Group decreased their price objective on Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a report on Monday, October 20th. Argus restated a “buy” rating and set a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $195.00.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.